Manara - Qatar Research Repository
10.1038_s41531-021-00203-9.pdf (1.36 MB)

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Download (1.36 MB)
journal contribution
submitted on 2024-04-29, 09:17 and posted on 2024-04-29, 09:17 authored by Luis M. A. Oliveira, Thomas Gasser, Robert Edwards, Markus Zweckstetter, Ronald Melki, Leonidas Stefanis, Hilal A. Lashuel, David Sulzer, Kostas Vekrellis, Glenda M. Halliday, Julianna J. Tomlinson, Michael Schlossmacher, Poul Henning Jensen, Julia Schulze-Hentrich, Olaf Riess, Warren D. Hirst, Omar El-Agnaf, Brit Mollenhauer, Peter Lansbury, Tiago F. Outeiro

With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.

Other Information

Published in: npj Parkinson's Disease
See article on publisher's website:



  • English


Springer Nature

Publication Year

  • 2021

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Bin Khalifa University
  • Qatar Biomedical Research Institute - HBKU
  • Neurological Disorders Research Center - QBRI

Usage metrics

    Qatar Biomedical Research Institute - HBKU



    Ref. manager